At 19.0% CAGR, the Asia Pacific Bioprocess Technology Market is projected to be worth US$ 11,000.75 million by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific bioprocess technology market was valued at US$ 4,608.64 million in 2023 and is expected to reach US$ 11,000.75 million by 2028, registering a CAGR of 19.0% from 2023 to 2028. Introducing advanced bioprocess technologies and emergence of automated real‐time flow cytometry (ART‐FCM) are the critical factors attributed to the Asia Pacific bioprocess technology market expansion.               

Advanced bioprocess technologies bridge R&D with production. Several players are introducing a wide range of new bioprocessing technologies in the market. On December 4, 2020, IDBS (a provider of software informatics solutions for the biotech and pharmaceutical industries) announced the launch of Polar. Polar creates a new product category called BioPharma Lifecycle Management (BPLM) to streamline drug development and production in biopharma research. Polar is designed and deployed to rapidly solve challenges associated with workflow, process quality, collaboration, and data analysis that have plagued the existing software solutions, including laboratory information management system (LIMS) and electronic laboratory notebook (ELN). As a result, there will be less human errors and an improvement in overall accuracy. It will reduce manual data processing and transcription, leading to fewer human errors and enhanced overall accuracy. It also has extensive search features that make it easier for users to locate what they are searching for, preventing the need for pointless duplication of effort. METTLER TOLEDO’s Dynochem Biologics is a purpose-built simulation software that supports upstream and downstream unit activities in bioprocessing at any scale. Bioprocess engineers and scientists use the software to choose appropriate process operating parameters and establish scales equivalency. Utilities enable quick evaluation of equipment performance with minimal data, whereas more potent models leverage the existing data streams for process characterization. Initial projects can be completed quickly with the help of responsive application expertise, rich training resources, and a model library that is already built. Peptides, mAbs, vaccinations, and viral vectors are a few examples of the many applications. Merck’s new BioContinuum Platform advances biotherapeutic drug manufacturing through improved efficiency, simplified plant operations, and greater quality and consistency. In addition, Merck’s Pellicon Single-Pass Tangential Flow Filtration aid in intensifying operations associated with the purification of therapeutic proteins. Thus, the introduction of various new-age bioprocess technologies is likely to provide lucrative opportunities for the market growth during the forecast period.  

On the contrary, stringent regulatory policies hurdles the growth of Asia Pacific Bioprocess technology market.

Based on type, the Asia Pacific bioprocess, technology market is segmented into cell culture media bioprocess, chromatography bioprocess, and consumables & accessories, and others. The consumables and accessories segment held 45.1% share of Asia Pacific Bioprocess technology market in 2023, amassing US$ 2,079.35 million. It is projected to garner US$ 4,941.53 million by 2028 to expand at 18.9% CAGR during 2023–2028.

Based on modality, the Asia Pacific bioprocess technology market is bifurcated into single use and multiple use. The single use segment held 78.1% share of Asia Pacific bioprocess technology market in 2023, amassing US$ 3,601.54 million. It is projected to garner US$ 8,438.38 million by 2028 to expand at 18.6% CAGR during 2023–2028.

Based on end-use, the Asia Pacific Bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. The biopharmaceutical companies segment held 53.1% share of Asia Pacific bioprocess technology market in 2023, amassing US$ 2,446.29 million. It is projected to garner US$ 5,770.44 million by 2028 to expand at 18.7% CAGR during 2023–2028.  

Based on country, the Asia Pacific bioprocess technology market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.2% share of Asia Pacific bioprocess technology market in 2023. It was assessed at US$ 1,345.72 million in 2023 and is likely to hit US$ 3,184.72 million by 2028, exhibiting a CAGR of 18.8% during the forecast period.  

Key players profiled in the Asia Pacific bioprocess technology market report are Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; STAMM Biotech; and Thermo Fisher Scientific Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com